Literature DB >> 33334855

Non-EPI versus Multishot EPI DWI in Cholesteatoma Detection: Correlation with Operative Findings.

J C Benson1, M L Carlson2, J I Lane3.   

Abstract

BACKGROUND AND
PURPOSE: Although multishot EPI (readout-segmented EPI) has been touted as a robust DWI sequence for cholesteatoma evaluation, its efficacy in disease detection compared with a non-EPI (eg, HASTE) technique is unknown. This study sought to compare the accuracy of readout-segmented EPI with that of HASTE DWI in cholesteatoma detection.
MATERIALS AND METHODS: A retrospective review was completed of consecutive patients who underwent MR imaging for the evaluation of suspected primary or recurrent/residual cholesteatomas. Included patients had MR imaging examinations that included both HASTE and readout-segmented EPI sequences and confirmed cholesteatomas on a subsequent operation. Two neuroradiologist reviewers assessed all images, with discrepancies resolved by consensus. The ratio of signal intensity between the cerebellum and any observed lesion was noted.
RESULTS: Of 23 included patients, 12 (52.2%) were women (average age, 47.8 [SD, 25.2] years). All patients had surgically confirmed cholesteatomas: Six (26.1%) were primary and 17 (73.9%) were recidivistic. HASTE images correctly identified cholesteatomas in 100.0% of patients. On readout-segmented EPI sequences, 16 (69.6%) were positive, 5 (21.7%) were equivocal, and 2 (8.7%) were falsely negative. Excellent interobserver agreement was noted between reviews on both HASTE (κ = 1.0) and readout-segmented EPI (κ = 0.9) sequences. The average signal intensity ratio was significantly higher on HASTE than in readout-segmented EPI, facilitating enhanced detection (mean difference 0.5; 95% CI, 0.3-0.8; P = .003).
CONCLUSIONS: HASTE outperforms readout-segmented EPI in the detection of primary cholesteatoma and disease recidivism.
© 2021 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2020        PMID: 33334855      PMCID: PMC7959419          DOI: 10.3174/ajnr.A6911

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  The diagnostic value of diffusion-weighted magnetic resonance imaging in detecting a residual cholesteatoma.

Authors:  Mark C J Aarts; Maroeska M Rovers; Erwin L van der Veen; Anne G M Schilder; Geert J M van der Heijden; Wilko Grolman
Journal:  Otolaryngol Head Neck Surg       Date:  2010-07       Impact factor: 3.497

2.  Value of DW-MRI in the preoperative evaluation of congenital cholesteatoma.

Authors:  Shinsuke Ide; Akira Ganaha; Tetsuya Tono; Takashi Goto; Noriaki Nagai; Keiji Matsuda; Minako Azuma; Toshinori Hirai
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-05-23       Impact factor: 1.675

Review 3.  The utility of diffusion-weighted imaging for cholesteatoma evaluation.

Authors:  K M Schwartz; J I Lane; B D Bolster; B A Neff
Journal:  AJNR Am J Neuroradiol       Date:  2010-05-20       Impact factor: 3.825

4.  Recidivous cholesteatoma: DWI MR after canal wall up and canal wall down mastoidectomy.

Authors:  T Bakaj; L Bakaj Zbrozkova; R Salzman; M Tedla; I Starek
Journal:  Bratisl Lek Listy       Date:  2016       Impact factor: 1.278

5.  Contemporary non-echo-planar diffusion-weighted imaging of middle ear cholesteatomas.

Authors:  Fernando Más-Estellés; Manuel Mateos-Fernández; Blanca Carrascosa-Bisquert; Fernando Facal de Castro; Iciar Puchades-Román; Constantino Morera-Pérez
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

6.  Negative Predictive Value of Non-Echo-Planar Diffusion Weighted MR Imaging for the Detection of Residual Cholesteatoma Done at 9 Months After Primary Surgery Is not High Enough to Omit Second Look Surgery.

Authors:  Roelof J Horn; Jan Willem C Gratama; Hester J van der Zaag-Loonen; Kitty E Droogh-de Greve; Peter-Paul G van Benthem
Journal:  Otol Neurotol       Date:  2019-08       Impact factor: 2.311

7.  The value of diffusion-weighted MR imaging in the diagnosis of primary acquired and residual cholesteatoma: a surgical verified study of 100 patients.

Authors:  Jean-Philippe Vercruysse; Bert De Foer; Marc Pouillon; Thomas Somers; Jan Casselman; Erwin Offeciers
Journal:  Eur Radiol       Date:  2006-03-03       Impact factor: 5.315

8.  Cholesteatoma vs granulation tissue: a differential diagnosis by DWI-MRI apparent diffusion coefficient.

Authors:  M Cavaliere; Antonella Miriam Di Lullo; E Cantone; G Scala; A Elefante; C Russo; L Brunetti; G Motta; M Iengo
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-08-07       Impact factor: 2.503

9.  Middle ear congenital cholesteatoma: systematic review, meta-analysis and insights on its pathogenesis.

Authors:  Nelson Gilberto; Sara Custódio; Tiago Colaço; Ricardo Santos; Pedro Sousa; Pedro Escada
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-18       Impact factor: 2.503

10.  Cholesteatoma: multishot echo-planar vs non echo-planar diffusion-weighted MRI for the prediction of middle ear and mastoid cholesteatoma.

Authors:  Cristina Dudau; Ashleigh Draper; Maria Gkagkanasiou; Geoffrey Charles-Edwards; Irumee Pai; Steve Connor
Journal:  BJR Open       Date:  2019-01-10
View more
  3 in total

1.  Retinal and optic nerve magnetic resonance diffusion-weighted imaging in acute non-arteritic central retinal artery occlusion.

Authors:  Matthew Boyko; Oana Dumitrascu; Amit M Saindane; Joseph M Hoxworth; Ranliang Hu; Tanya Rath; Wesley Chan; Alexis M Flowers; Ehab Harahsheh; Parth Parikh; Omer Elshaigi; Benjamin I Meyer; Nancy J Newman; Valérie Biousse
Journal:  J Stroke Cerebrovasc Dis       Date:  2022-07-15       Impact factor: 2.677

2.  Detection of cholesteatoma: 2D BLADE turbo gradient- and spin-echo imaging versus readout-segmented echo-planar diffusion-weighted imaging.

Authors:  Mengyan Lin; Naier Lin; Yaru Sheng; Yan Sha; Zhongshuai Zhang; Kun Zhou
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-28       Impact factor: 3.236

3.  Current insights of applying MRI in Graves' ophthalmopathy.

Authors:  Cheng Song; Yaosheng Luo; Genfeng Yu; Haixiong Chen; Jie Shen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-29       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.